Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05562349 · ClinicalTrials.gov registry record · Phase 2
Clavulanic Acid for the Treatment of Cocaine Use Disorder
A Phase 2 study of Cocaine Dependence, sponsored by Temple University.
- Active
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 2
- Study locations
NCT05562349: Active Phase 2 study of Cocaine Dependence, sponsored by Temple University.
NCT05562349 is a Phase 2 study of Cocaine Dependence that is active but no longer recruiting, run by Temple University. The registered enrollment target is 65 participants, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05562349, a Phase 2 study of Cocaine Dependence, is active but no longer recruiting, sponsored by Temple University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 2
- Study locations
Study Summary
A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)
Primary Outcome
Cocaine-free weeks are measured by self-report using Timeline Follow Back (TLFB) and confirmed by urine drug screen.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Clavulanic Acid Only Product
Study Locations (2)
Pennsylvania
- University of Pennsylvania - Philadelphia
South Carolina
- MUSC - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2024-07 |
| Phase | Phase 2 |
What the registry record for NCT05562349 still lists
NCT05562349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05562349 reports a single indexed study location in Pennsylvania, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05562349 about?
NCT05562349 is a clinical study titled "Clavulanic Acid for the Treatment of Cocaine Use Disorder". A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)
What is the current status of trial NCT05562349?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2023-05-03. Estimated completion is 2024-07.
What conditions does trial NCT05562349 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT05562349?
The interventions under investigation include: Placebo (DRUG), Clavulanic Acid Only Product (DRUG).
Who is sponsoring clinical trial NCT05562349?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05562349 being conducted?
This trial has 2 study locations across Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05562349's enrollment target sits among peer trials
65 23rd of 38 higher than 16 of 38 other Cocaine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Clinical Trial of Topiramate for Cocaine Addiction
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI